CENTOGENE Reports Full Year 2023 Financial Results and Recent Business Highlights
Centogene N.V. - Common Shares (CNTG)
Last centogene n.v. - common shares earnings: 12/5 06:28 am
Check Earnings Report
Company Research
Source: GlobeNewswire
Reported Full Year 2023 total revenues of 2% growth at €48.5 millionSecured approximately USD 20 million – strengthening cash position and expanding relationship with Lifera, a biopharma company owned by the PIFPositioned for strong performance in 2024, driven by new and existing Pharma business and solid Diagnostic growth in line with industry standards; guidance of FY2024 total revenue growth between 10-15%Ongoing strategic alternatives process focused on sustainable long-term value creation for the benefit of its stakeholders CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 15, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“we” or the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced financial results for the fiscal year ended December 31, 2023, and provided a business update. “In 2023, we focused on strategic growth – strengthening our Diagnostic portfolio and introducing new data and w
Show less
Read more
Impact Snapshot
Event Time:
CNTG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CNTG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CNTG alerts
High impacting Centogene N.V. - Common Shares news events
Weekly update
A roundup of the hottest topics
CNTG
News
- C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development [Yahoo! Finance]Yahoo! Finance
- C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug DevelopmentGlobeNewswire
- CENTOGENE Announces Adoption of All Resolutions Tabled at 2024 Annual General Meeting [Yahoo! Finance]Yahoo! Finance
- CENTOGENE Announces Adoption of All Resolutions Tabled at 2024 Annual General MeetingGlobeNewswire
- Global Rare Disease Diagnostics Market is Projected to Hit USD 88,969.27 Million by 2032, With a CAGR of 9.2% From 2024 to 2032- Report by Polaris Market Research (PMR) [Yahoo! Finance]Yahoo! Finance
CNTG
Sec Filings
- 6/20/24 - Form 6-K
- 5/31/24 - Form 6-K
- 5/29/24 - Form 6-K
- CNTG's page on the SEC website